Business Context and Reporting Period
This Form 8-K reports on the 2010 Annual Meeting of Stockholders for PharmAthene, Inc., held on June 23, 2010. The filing details the election of directors and the ratification of the independent auditor. Note: The input metadata references "Altimmune, Inc.," but the filing text explicitly identifies the registrant as "PharmAthene, Inc."
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on corporate governance events.
Material Changes and Voting Results
The following directors were elected to serve until the 2011 annual meeting:
- Common Stock Directors: John Pappajohn, John Gill, Joel McCleary, Eric I. Richman, Jeffrey W. Runge, Mitchel Sayare, and Derace L. Schaffer. All received significant "Votes For" (ranging from approximately 11.75 million to 11.81 million) with minimal votes withheld.
- Noteholder Directors: James H. Cavanaugh and Steven St. Peter were elected by holders of the Company's 10% Notes, receiving 6,584,063 votes each with zero votes withheld.
Stockholders ratified the selection of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2010, with 21,286,874 votes in favor, 42,591 against, and 220,311 abstentions.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the corporate name discrepancy between the metadata (Altimmune, Inc.) and the filing (PharmAthene, Inc.).
- Confirm the total number of shares outstanding and the specific voting rights attached to the 10% Notes.
- Review the full proxy statement for details on director qualifications and any other proposals not detailed in this 8-K.